T3-T4 combo-therapy
-
The two T4-T3 ratios that confine thyroid therapy
Here are the two most pervasive, limiting, and potentially harmful presumptions about T3:T4 hormone ratios in thyroid science today. Ratio #1: There is a perfect physiological T4:T3 ratio secreted from the healthy human thyroid gland, and it is approximately 15:1. (Various ratios are cited, most often from 13:1 to 16:1) Ratio #2: In the…
-
2014 ATA Therapy guidelines: 4. Using Synthetic T3
This post continues my paraphrase of Jonklaas et al’s 2014 “Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement.” Posts in this series: 2014 ATA Thyroid therapy guidelines: 1. Levothyroxine 2014 ATA Thyroid therapy guidelines: 2. Ethics 2014 ATA Therapy guidelines: 3. Desiccated thyroid 2014 ATA…
-
Part 5: All thyroid meds are bioidentical, but individual response varies widely
This post concludes my response to a misleading video (10). THYROID HORMONE PHARMACEUTICALS A suspicion many people have is that thyroid hormone pharmaceuticals are very different from the thyroid hormones our bodies produce. Let’s look into the claim that they are “bioidentical” in structure and function. Synthetic thyroid hormone has a counter-clockwise rotated molecule (it…
-
Endocrinology network news reviews study on T3-based therapy prescribing
Good post on “Endocrinology Network” news, summarizing of research and trends regarding T3-based thyroid medication prescriptions for hypothyroidism around the world (not mentioning Canada, though). Fuerst, M. (2019, February 14). Physician–patient interaction may influence prescribing patterns in hypothyroidism | Endocrinology Network. Retrieved February 25, 2019, from http://www.endocrinologynetwork.com/thyroid-disorders/physicianpatient-interaction-may-influence-prescribing-patterns-hypothyroidism Apparently, In the United States, in 2017, “approximately…
-
Dirty Money “Drug Short” episode and thyroid T3 Liothyronine
In the “Dirty Money” series on Netflix, the “Drug Short” episode (1) helped me understand some of the economic forces that may have influenced T3 / Liothyronine price hikes in the UK. It makes me concerned about the future of T3 pricing in Canada too. This episode focuses on Valeant, a Canadian pharmaceutical company that…